The Claim
Supraphysiologic doses of levothyroxine (300 mcg daily) can maintain radiographic stability in TSH-secreting pituitary adenomas for up to 20 years, indicating that not all TSHomas are uniformly resistant to thyroid hormone feedback and demonstrating biological heterogeneity in tumor responsiveness.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In one case, a 65-year-old woman with a TSH-secreting pituitary tumor had no tumor growth for 20 years while taking high-dose levothyroxine, showing that some of these tumors can respond to thyroid hormone therapy.
See the scientific wording
A 65-year-old woman with a 9-11 mm TSH-secreting pituitary adenoma remained radiographically stable for 20 years while receiving supraphysiologic doses of levothyroxine (300 mcg daily), challenging the assumption that all TSHomas are uniformly resistant to thyroid hormone feedback and suggesting biological heterogeneity in tumor responsiveness.
High doses of thyroid hormone enter the pituitary gland and bind to specific receptors on tumor cells, which turns down the production of the hormone that stimulates the thyroid. This reduction in stimulating hormone slows the growth of the tumor, keeping it stable over many years.
What the research says
1 studyA woman with a rare brain tumor that makes too much thyroid-stimulating hormone was given very high doses of thyroid hormone for 20 years — and the tumor didn’t grow. This suggests that, contrary to what doctors thought, some of these tumors can still listen to thyroid hormone signals.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.